Results 271 to 280 of about 137,002 (346)

Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction. [PDF]

Cardiooncology
Scalia IG, Ibrahim R, Abdelnabi M, Pham HN, Farina JM, Pietri MP, Lee KS, Tamarappoo BK, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea. [PDF]

Curr Opin Pulm Med
D'Annibale DA, Mimoto M, McCowen KC, Malhotra A.   +3 more
europepmc   +1 more source

Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction? [PDF]

Cardiovasc Endocrinol Metab
Jacob S, Eckel RH, Krentz AJ.
europepmc   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. [PDF]

J Neurol Neurosurg Psychiatry
De Giorgi R, Ghenciulescu A, Yotter C, Taquet M, Koychev I.   +4 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates. [PDF]

Card Fail Rev
Abdelhamid M, Abdrabou MM, Faris E, El Kafas S, Hosny M, Hassan A.   +5 more
europepmc   +1 more source